FY2026 results and strategic progress — what management presented
In its FY2026 full year results investor webinar, AnteoTech Managing Director and CEO Merrill Gray outlined the company’s financial performance and commercial progress on 30 September 2026. The Brisbane-based company operates a single proprietary chemical platform, commercialised across a product suite including AnteoBind™, Anteo X®, Anteo S™, Anteo C, and the Ultranode™ range, targeting two global markets: life sciences and advanced battery technologies.
The presentation noted a market capitalisation of $56 million as at 23 September 2026 and a cash position of $11.2 million as at 30 June 2026. Management framed FY2026 as a year of commercialisation build-out, cost discipline, and pipeline expansion, with FY2027 positioned as the conversion year.
When big ASX news breaks, our subscribers know first
FY2026 financial performance — costs cut, losses narrowed
The presentation detailed three headline financial trends across the period: sales revenue, total revenue, and operating expenses. Sales revenue for FY2026 came in at $467,589, compared with $968,878 in FY2025. Management noted the FY2025 figure included a one-off additional Serum Institute of India (SII) payment of $276,863, making a direct year-on-year comparison misleading without that context. A further $134,138 SII sale completed on 7 July 2026 will be recognised in FY2027, not FY2026.
Operating expenses fell for the second consecutive year, and the net loss narrowed from $6,759,135 in FY2025 to $5,375,654 in FY2026, reflecting the company’s sustained focus on cost reduction.
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Sales Revenue | $460,397 | $968,878* | $467,589^ |
| Total Revenue | $4,346,185 | $3,458,728 | $3,129,144 |
| Operating Expenses | $10,892,231 | $8,451,114 | $6,857,881 |
| Net Loss | — | ($6,759,135) | ($5,375,654) |
*FY2025 includes an additional SII payment of $276,863. ^A further $134,138 SII sale completed 7 July 2026 will be recognised in FY2027. Operating expenses exclude non-cash items (depreciation, amortisation, and share-based payments).
What is AnteoTech’s technology — and why does it matter?
AnteoTech’s competitive advantage centres on a single surface chemistry platform based on coordination bonding, a process that attaches antibodies and proteins to surfaces with greater precision. This underpins all of the company’s products across two distinct industries.
In life sciences, AnteoBind™ and AnteoBind™ NXT enable more sensitive and reproducible diagnostic test results across lateral flow, ELISA, chemiluminescence immunoassay (CLIA), and biosensor formats. The global in vitro diagnostics (IVD) market is valued at approximately US$56 billion per annum and is growing at a 9% CAGR, according to figures cited in the presentation.
In advanced battery technologies, the same platform chemistry is applied across multiple battery components. The presentation outlined the Ultranode™ product tiers and their target applications:
- Ultranode™ X — automotive and eVTOL applications, targeting high cycle life
- Ultranode™ 70 — consumer electronics and micro-mobility (3C markets)
- Ultranode™ 95 — drones, defence, and M/UAS applications requiring maximum energy density
Beyond the Ultranode™ range, the company also supplies Anteo X® (cross-linker for silicon anodes), Anteo S™ (cross-linker for ceramic coated separators), Anteo C (primer coating additive for current collector foils), and SiMRAX (a combination Anteo X and single-walled carbon nanotube product). Target markets highlighted include high silicon anodes (US$540 million, 45% CAGR) and ceramic coated separators (US$2 billion, 21% CAGR).
Commercial pipeline and FY2027 priorities
The presentation included a pipeline snapshot as at 7 September 2026, representing the most forward-looking commercial signal in the webinar:
- Life Sciences: 94 leads | 124 MQLs | 28 SQLs | 31 samples under evaluation
- Advanced Battery Technologies: 22 leads | 51 MQLs | 29 SQLs | 32 samples under evaluation
Management described FY2027 as a “Sales Conversion” priority year, with commercial activity across both divisions aimed at translating this pipeline into contracted revenue.
Life sciences — converting evaluations into contracted revenue
The presentation highlighted active customer engagement across multiple geographies. In India, the company is working to expand its SII relationship, with an AnteoBind™ NXT activated ELISA plate prototype currently under evaluation. In the US, management identified Point-of-Care, CLIA, and ELISA markets as priority targets. In Europe, a collaboration with a large global life sciences company on CLIA is underway. Japan and South Korea are supported by distributor networks, with Cosmo Bio (Japan, 2026) and KOMA (South Korea, 2015) both referenced in the presentation.
The CLIA development program milestone reached in June 2026 marked the first commercial income from the large global life sciences collaboration, with AnteoBind NXT demonstrating up to six times lower capture antibody usage versus conventional methods, a cost advantage directly relevant to a market where antibodies can represent up to 35% of total assay costs.
Advanced battery technologies — JDAs, drone market, and new product sales
The presentation detailed several active commercial engagements in this division:
- Two Ultranode™ 95 drone anode joint development agreements (JDAs) are under negotiation in the US
- The Battery Innovation Center (BIC) commercial scale-up validation programme for Ultranode™ 95 is underway
- Wyon (Europe) is evaluating Ultranode™ 70 in a commercial cell format
- SiMRAX is in customer trials with Black Diamond Structures
- Airspeeder supply collaboration and partnerships are in development
- Anteo S™, Anteo C, and Anteo X® sales conversion efforts are progressing, including within SiMRAX
- Xerabrid (South Korea, 2026) is referenced in the Advanced Battery Technologies division
Ultranode 95 validation at the Battery Innovation Center in Indiana confirmed more than 300 cycles at 70% capacity retention in commercial 5 Ah pouch format cells, with BIC describing the scale-up as one of the most straightforward it had observed, providing the independent third-party data now underpinning the two US JDA negotiations.
Upcoming commercial engagements
The presentation also outlined three near-term events for investor awareness:
- NIPER India technical webinar — 6 October 2026 (lateral flow and paper-based diagnostics)
- North American Battery Show, Detroit — 12–15 October 2026 (Anteo C focus)
- MEDICA, Düsseldorf — 16–19 November 2026
Investment considerations — disciplined path toward commercialisation
The presentation highlighted several metrics relevant to investors assessing AnteoTech’s progress as a commercialisation-stage company:
- Operating expenses have been reduced over two years, from $10,892,231 in FY2024 to $6,857,881 in FY2026, reflecting sustained financial discipline.
- The net loss narrowing trajectory (from $6.76 million to $5.38 million) is supported by a cash position of $11.2 million as at 30 June 2026.
- The commercial pipeline as at September 2026 comprised 28 SQLs and 31 samples under evaluation in Life Sciences, and 29 SQLs and 32 samples under evaluation in Advanced Battery Technologies.
- The technology platform is protected by 17 granted patents and is validated across multiple formats and geographies.
The company remains loss-making, and profitability is not imminent. Management’s stated FY2027 focus on sales conversion represents the key catalyst to watch, with the pipeline metrics above providing the clearest indicator of progress toward that objective.
Stay Ahead on ASX Healthcare and Tech News
Big News Blast delivers FREE breaking ASX announcements straight to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers who stay ahead of the market on every major move. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.